ReviewCellular and molecular life sciences : CMLS2013
Serotype-independent pneumococcal vaccines.
Review in Cellular and molecular life sciences : CMLS, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.
- Pooled it
- ZPY-CpG-Ch, a broad coverage vaccine againstScience advances · 2026Article
- Review
- Analysis of lipoprotein SPD_0792 fromBioinformation · 2025Article
- Biological puzzles solved by usingJournal of bacteriology · 2024Review
- Novel method for production and purification of untagged pneumococcal surface protein A from clade 1.Applied microbiology and biotechnology · 2024Article
- Article
- Advances in immune response to pulmonary infection: Nonspecificity, specificity and memory.Chronic diseases and translational medicine · 2023Review
- Synthetic Zwitterionic Streptococcus pneumoniae Type 1 Oligosaccharides Carrying Labile O-Acetyl Esters.Angewandte Chemie (International ed. in English) · 2023Article
- Peptide linker increased the stability of pneumococcal fusion protein vaccine candidate.Frontiers in bioengineering and biotechnology · 2023Article
- High prevalence of multiple serotypes of pneumococci in patients with pneumonia and their associated risk factors.Thorax · 2022Article
- ClearColi as a platform for untagged pneumococcal surface protein A production: cultivation strategy, bioreactor culture, and purification.Applied microbiology and biotechnology · 2022Article
- Review
- Impaired mucociliary motility enhances antigen-specific nasal IgA immune responses to a cholera toxin-based nasal vaccine.International immunology · 2020Article
- New Strategy Is Needed to Prevent Pneumococcal Meningitis.The Pediatric infectious disease journal · 2020Article
- Development of Next GenerationVaccines · 2020Review
- [Regional System for Vaccines (SIREVA), laboratory surveillance and vaccine development forRevista panamericana de salud publica = Pan American journal of public health · 2020Article
- Evaluation of inactivated Bordetella pertussis as a delivery system for the immunization of mice with Pneumococcal Surface Antigen A.PloS one · 2020Article
- The Modified Surface Killing Assay Distinguishes between Protective and Nonprotective Antibodies to PspA.mSphere · 2019Article
- Pneumococcal Vaccines.Microbiology spectrum · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Streptococcus pneumoniae remains an important cause of disease with high mortality and morbidity, especially in children and in the elderly. The widespread use of the polysaccharide conjugate vaccines in some countries has led to a significant decrease in invasive disease caused by vaccine serotypes, but an increase in disease caused by non-vaccine serotypes has impacted on the overall efficacy of these vaccines on pneumococcal disease. The obvious solution to overcome such shortcomings would be the development of new formulations that provide serotype-independent immunity. This review focuses on the most promising approaches, including protein antigens, whole cell pneumococcal vaccines, and recombinant bacteria expressing pneumococcal antigens. The protective capacity of these vaccine candidates against the different stages of pneumococcal infection, including colonization, mucosal disease, and invasive disease in animal models is reviewed. Some of the human trials that have already been performed or that are currently ongoing are presented. Finally, the feasibility and the possible shortcomings of these candidates in relation to an ideal vaccine against pneumococcal infections are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.